A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Go deeper with Bing News on:
- Just one bad night's sleep 'raises levels of an Alzheimer's biomarker by 17%'on January 9, 2020 at 7:16 am
READ MORE: Alzheimer's vaccine could be trialled on humans in two years “Many of us experience sleep ... such sleep deprivation could possibly have detrimental effects.” In the UK, 850,000 people live ...
- Possible dementia vaccine on horizonon January 6, 2020 at 6:24 am
A preventive vaccine for dementia may be closer than expected as from 2020 if signals from medical researchers at the Institute for Molecular Medicine and the University of California, Irvine, UCI, ...
- Alzheimer's vaccine could be trialled on humans in two yearson January 2, 2020 at 4:12 pm
An Alzheimer’s vaccine may be tested in human trials in as little as two years, scientists have claimed. A team from the University of California, Irvine, developed a jab that removed tell-tale ...
- A New Alzheimer’s Vaccine Could Be Headed for Human Trialson January 2, 2020 at 9:02 am
Cognitive decline has been part of the aging process for all of human history, but a team of researchers from Australia says a new vaccine cocktail could finally prove an effective tool to combat ...
- Dementia prevention vaccine ready for human trials, researchers sayon January 1, 2020 at 2:24 pm
TORONTO -- A vaccine designed to prevent dementia is ready to enter the human trial stage within two years after successful tests on mice, researchers say. The study, published in the journal ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- U.S. appeals court rebuffs Leander firefighter who was fired after refusing vaccineon January 9, 2020 at 8:10 pm
The disagreement arose when the city adopted a 2016 policy requiring all personnel to receive the TDAP vaccine, which immunizes against tetanus, diphtheria and pertussis (whooping cough). This time, ...
- Opinion: HPV vaccine provides safe, effective protection for adults and childrenon January 9, 2020 at 6:27 pm
Within the last five years, the U.S. Food and Drug Administration (FDA) approved a new HPV vaccine, and later expanded the recommended age range for its administration, resulting in more robust HPV ...
- More Americans Believe Measles Vaccine Is Safe and Healthy Optionon January 9, 2020 at 5:28 pm
Share on Pinterest More Americans say the benefits of vaccines outweigh the risk. Getty Images With vaccine-preventable diseases in the United States on the rise, more people say they believe the ...
- Hundreds of Seattle students without updated vaccine records at deadlineon January 9, 2020 at 3:13 pm
SEATTLE — The number of Seattle Public Schools students with up-to-date vaccine records continues to rise after the district passed its deadline to exclude students without proper paperwork. As of ...
- Moderna Sees Positive Results on Vaccine for Disease That Can Cause Birth Defectson January 9, 2020 at 1:03 pm
The biotech company Moderna is inching closer to commercialization, with positive new interim data on the Phase 1 study of its Cytomegalovirus vaccine and news that the company had dosed the first ...